Physician profile
Cheri Call
NPI 1043706872
$6,464.77
in general payments reported to CMS, 2019-2025
24 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,398 · 2022: $1,288 · 2023: $1,735 · 2024: $1,021 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,413.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $741.37 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Otsuka America Pharmaceutical, INC. | $674.68 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $445.99 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $443.71 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $416.75 | 2021-2025 | Trintellix |
| Corium, LLC | $415.42 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $313.35 | 2021-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310.89 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $260.14 | 2021-2022 | |
| Alkermes, INC. | $196.23 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $163.87 | 2021-2025 | Uzedy, Austedo |
| Neos Therapeutics, LP | $139.25 | 2021-2024 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $102.87 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $92.41 | 2021-2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $76.52 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $76.13 | 2025 | Jornay Pm |
| Janssen Biotech, INC. | $59.18 | 2023 | |
| Eisai INC. | $30.94 | 2021 | |
| Tris Pharma INC | $22.78 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $20.12 | 2022 | |
| Neurocrine Biosciences, INC. | $16.95 | 2024 | Ingrezza |
| Adlon Therapeutics L.P. | $15.84 | 2021 | |
| Hikma Pharmaceuticals USA | $15.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.